Registration Dossier

Toxicological information


Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Additional information

Of the 41 female mice administered with 0.6mgTEL, survving at 36 weeks, animals (12%) developedmalignant lymphomasbetween the 36th and 51st weeks (control: 0 of 48).Lymphomas developed in one of 26 males in this dose group (compared to 1 in 26 of control group).

 In the male animals at this dose group,one out of 26 animals developed lymphomas (control 1 of 46). 

While for other tumour types no significant differences between control and dose group were observed, malignant lymphoma tumours in female mice significantly increased

Justification for classification or non-classification

There is no relevant information on the carcinogenicity of TEL. No classification under EU DSD or GHS/is warranted.